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Blink rate is associated with drug-induced
parkinsonism in patients with severe
mental illness, but does not meet
requirements to serve as a clinical test: the
Curacao extrapyramidal syndromes study
XIII
Charlotte L. Mentzel1,2*, P. Roberto Bakker1,2, Jim van Os1,3, Marjan Drukker1, Glenn E. Matroos4,
Marina A. J. Tijssen5 and Peter N. van Harten1,2
Abstract
Background: Drug-induced parkinsonism (DIP) has a high prevalence and is associated with poorer quality of life.
To find a practical clinical tool to assess DIP in patients with severe mental illness (SMI), the association between
blink rate and drug-induced parkinsonism (DIP) was assessed.
Methods: In a cohort of 204 SMI patients receiving care from the only mental health service of the previous Dutch
Antilles, blink rate per minute during conversation was assessed by an additional trained movement disorder specialist.
DIP was rated on the Unified Parkinson’s Disease Rating Scale (UPDRS) in 878 assessments over a period of 18 years.
Diagnostic values of blink rate were calculated.
Results: DIP prevalence was 36%, average blink rate was 14 (standard deviation (SD) 11) for patients with DIP, and 19
(SD 14) for patients without. There was a significant association between blink rate and DIP (p < 0.001). With a blink
rate cut-off of 20 blinks per minute, sensitivity was 77% and specificity was 38%. A 10% percentile cut-off model resulted
in an area under the ROC curve of 0.61. A logistic prediction model between dichotomous DIP and continuous blink
rate per minute an area under the ROC curve of 0.70.
Conclusions: There is a significant association between blink rate and DIP as diagnosed on the UPDRS. However, blink
rate sensitivity and specificity with regard to DIP are too low to replace clinical rating scales in routine psychiatric practice.
Trial registration: The study was started over 20 years ago in 1992, at the time registering a trial was not common
practice, therefore the study was never registered.
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Background
Drug-induced parkinsonism (DIP) prevalence in patients
with severe mental illness (SMI) varies between 36% [1]
and 56% [2], and is associated with a poorer quality of
life [3], falls [4] and antipsychotic non-compliance [5].
However, DIP is poorly recognised and both DIP and
Parkinson’s disease (PD) rating scales requiring lengthy
training sessions are difficult to implement, hence rating
scales are not suitable for clinical practice [6]. Therefore,
simple and easy to use diagnostic methods for DIP are
warranted. Diagnostic methods based on blink rate as a
clinical test for diagnosing DIP would be a good measure
because: (i) the assessment of blink rate during conver-
sation is easy and quick, (ii) requires no specialised
equipment, (iii) has a high interrater reliability [7],,
and (iv) research in PD has shown that reduced blink
rate during conversation discriminates well between
PD and healthy controls when compared to the Unified
Parkinson’s Disease Rating Scale (UPDRS) [8]. Blink rate
may be easily measured with the use of mobile apps, thus
enabling clinicians to diagnose DIP.
D2-receptor involvement has been linked consistently
to spontaneous blink rate, both in human and animal
experiments [9]. In their 1990 seminal paper, Karson et
al. [7] conclude that blinks are most likely generated in
the pontine reticular formation and signals are then
transmitted to the lateral geniculate bodies. Since this
publication, to our knowledge, only three articles exam-
ining blink rate in schizophrenia have been published.
These studies linked blink rate to various neurological
soft signs (NSS) in patients [10–12] however no associ-
ation between blink rate and central dopaminergic activ-
ity was found in healthy controls [9]. While several
studies indicate that blink rate is a good clinical test for
the diagnosis of PD, as far as we know, no such study
has been published on the use of blink rate as a clinical
test for DIP in patients with severe mental illness (SMI).
The present paper aims to assess (i) the association
between DIP and blink rate, and (ii) the possibilities of
using blink rate as a clinical test to diagnose DIP with
the UPDRS [1, 13] as gold standard. As the goal of the
paper is to develop a clinical test to differentiate between
SMI patients with DIP and SMI patients without DIP,
patients were compared to other patients and no healthy
control group was used.
Methods
Subjects
All 204 patients hospitalized or receiving structured
outpatient care from the Dr. D.R. Capriles Clinic, the
only psychiatric hospital in the Dutch Antilles, in 1991
were asked to take part in the Curacao extra pyramidal
syndromes study, an 18 year (1993, 1994, 1996, 1997,
1998, 2001 and 2009) prospective naturalistic follow-up
study. Informed consent was obtained from all patients
and the protocol was approved by the Curaçao Institu-
tional Review Board. A total of 8 assessments focusing
on movement disorders and medication use were
performed over the 18 years follow-up. A detailed
description of the patients and assessments has been
published previously [1].
Inclusion criteria were a minimum age of 18 years,
and cumulative exposure to antipsychotics of at least 3
months; current antipsychotic use was not required.
Exclusion criteria were a history of neurological disor-
ders affecting motor function, including PD, and having
undergone a lobotomy. Patients with dementia (N = 7)
or mental retardation (N = 3) as primary diagnosis were
excluded. The total number of patients was 191 and the
dataset is available from the corresponding author upon
request.
Assessments
The UPDRS version 3.0 was used to define DIP [13].
Blink rate per minute was assessed for 1 min during
conversation at each measurement (N = 878) by one au-
thor with a stopwatch while the other author conducted
the interview (PvH and GM), a more detailed descrip-
tion of the test has been published previously [1]. Both
raters are psychiatrists specialized in movement disor-
ders. They were blind to the UPDRS score while blink
rate was being assessed and vice versa. An exact descrip-
tion of the test circumstances can be found in a previous
publication [1]. DIP was defined as (i) a score of at least
‘moderate’ (score 3, range 0–4) on one of the bradykine-
sia items (1, [2], 6–14) or two or more scores of ‘mild’
(score 2) on these items; (ii) a rigidity (item 3) or tremor
(item 4–5) score of at least ‘mild’. The more stringent
criteria used for bradykinesia were chosen as motor
slowness can also be caused by mental symptoms or
medication. Time points on which the patient scored
‘mild’ or higher on the blepharospasm item on the Burke
Fahn Marsden Dystonia Rating Scale (BFMDRS) were
excluded (N = 54), as blepharospasm can cause involun-
tary contractions in the eyelid and hence can be misclas-
sified as blink-related DIP. The BFMDRS was also
scored at all of the time points by the same raters (PvH
and GM). DSM-III-R diagnosis and demographic vari-
ables (age, sex, diagnosis, and antipsychotic type and
dose), were extracted from the case file by a trained
physician.
Statistical analyses
Analyses were carried out with Stata, version 12 [14].
Blink rate per minute was (i) used as a continuous vari-
able, (ii) dichotomised using a cut-off point of 20 blinks
per minute, as suggested by Fitzpatrick et al. [8], and (iii)
as 10% percentile cut-offs (hereafter: continuous and
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dichotomous blink rate, and 10% percentile blink rates,
respectively). Using both dichotomous blink rate and
10% percentile blink rates we calculated: (i) sensitivity
and specificity using the roctab (nonparametric ROC
analysis)command; (ii) positive predictive value (PPV)
and negative predictive value (NPV) using the diagt
(summary statistics for diagnostic tests compared to true
disease status) command. The association between blink
rate and DIP as a continuous variable was calculated
using the regress (linear regression) command. Areas
under the ROC curves were calculated: (i) for the 10%
percentile blink rate using the roctab command, and (ii)
for the continuous blink rate per minute using the lroc
(computes area under ROC curve and graph the curve)-
command based on the logistic prediction model using
the logit(logistic regression, reporting coefficients) com-
mand, with DIP as a dichotomous dependent variable
and continuous blink rate, age, sex, diagnosis (schizo-
phrenia or other) and antipsychotic defined daily dose
(DDD) [15] and type as independent variables.
Results
A total of 878 assessments in 191 patients were available
for analysis. All patients provided written informed con-
sent. Of the sample, 72% was male, 95% was of African-
Caribbean origin and 84% had a DSM-III-R diagnosis of
schizophrenia. The mean age was 53 years with a stand-
ard deviation (SD) of 15 years, DIP prevalence according
to the UPDRS was 36% (317 instances in 890 measure-
ments, mean severity 20 points on the UPDRS, SD 12),
DIP persisted to the next time point in 65% of cases.
Mean blink rate was 14 (SD 11) for patients with DIP,
and 19 (SD 14) for patients without DIP.
For the dichotomous blink rate, sensitivity (the test’s
ability to correctly designate a subject with the disease as
positive) was 77%, specificity (the test’s ability to correctly
designate a subject without the disease as negative) 38%,
PPV 75% (meaning there is a 75% probability that if a
patient’s blink rate is below 20 blinks per minute that pa-
tient does indeed have DIP), and NPV 41% (meaning there
is a 41% probability that if a patients blink rate is higher
than 20 blinks per minute, the patient does not have DIP)
(Table 1). For the 10% percentile blink rates sensitivity,
specificity, PPV and NPV are reported in Table 2. The area
under the ROC curve was 0.61 (Fig. 1). Linear regression
yielded significant coefficients between DIP and blink rate
(B − 0.14, p < 0.000) with an R-squared of explained vari-
ance of 0.025 or 2.5%. In the logistic regression prediction
model adjusted for age, sex, diagnosis, and antipsychotic
type and dose, R-squared explained variance was margin-
ally higher at 0.095 or 9.5% (Fig. 2 and Table 3). The ROC
derived from the prediction model yielded an area under
the curve of 0.70, slightly higher than the ROC of the 10th
percentile cut-off.
Discussion
The association between blink rate and DIP and UPDRS
score in patients with SMI is highly significant (p <
0.000). However, the explained variance of 9.5% of the
logistic regression model is too small, and sensitivity and
specificity of blink rate are too low for use as a clinical
tool in SMI patients. With the most efficient cut-off,
only 62% of patients was correctly classified by the blink
rate test. Other clinical parameters (that are easily
accessible to clinicians) that are known to affect DIP,
such as age, diagnosis, and sex, were added to a logistic
regression model. The variables displayed significant
associations with DIP, however the explained variance
was still too low for the model to be useful in a clinical
setting.
The present findings are in contrast with results found
in PD. Using the same cut off point of 20 blinks per mi-
nute, a meta-analysis [8] reported a sensitivity and speci-
ficity of 65% and 83%, respectively, whereas the present
study found a sensitivity and specificity of 77% and 38%,
respectively. A possible cause for the discrepancy is the
greater difference in mean blink rate between patients
with PD and healthy controls (18 versus 34 blinks) com-
pared to the difference between SMI patients with and
without DIP (14 versus 19 blinks) in the present study.
An explanation is that patients with PD and healthy con-
trols are distinct groups, without much overlap, whereas
the SMI patients in the present study originate from the
same population and have DIP on a continuous scale.
In the present study, SMI patients without DIP showed
a lower average blink rate per minute compared to healthy
controls from other studies with similar methodology.
This is surprising as studies have consistently shown that
patients with schizophrenia have a higher average blink
rate compared to healthy controls [7, 11, 12], with a blink
rate of 27 for patients with a psychotic disorder and
22–18 for other mental disorders [7]. Although this
difference is most striking in drug-naive patients with
a diagnosis of schizophrenia [7, 11, 12, 16], it is also
present in patients treated for schizophrenia [10, 12].
Furthermore, blink rate is associated with subsets of
Table 1 Drug-induced parkinsonism identified by the UPDRS as
gold standard, based on blink rate
Parkinsonism
UPDRS Blink rate no casea Blink rate case Total
No case 216 347 563
Case 74 241 315
total 290 588 878
Sensitivity: 77%, Specificity: 38%
Positive predictive value 75%,
Negative predictive value 41%
aThe cut-off for a case is 20 blinks per minute
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symptoms such as hallucinations and anxiety [10–12]
in patients with a diagnosis of schizophrenia. Associa-
tions with neurological soft signs [10, 11, 16] and
antipsychotic dose [16] have been inconsistent. It is
likely that blink rate in patients with schizophrenia is
influenced by more factors than just DIP. What these
factors are and how they relate to the current study
population remains unknown. Further investigation
into the pathophysiology of abnormal blink rates in
patients with a diagnosis of schizophrenia is war-
ranted as it could shed light on underlying disease
mechanisms.
Limitations
Due to the naturalistic setting, the well-defined catch-
ment area and the broad inclusion criteria, results from
this study are likely to be a good representation of
movement disorders in a real world SMI population;
Bakker et al. [17] found very similar results for medica-
tion use and movement disorders in a Dutch popula-
tion However, there are a number of limitations to
the study. First, blink rate varies with context and,
therefore, also varies between tests. Although no data
on inter-rater reliability was available in this study,
both Karson et al. [7] and Fitzpartrick et al. [8] re-
ported good inter-rater reliability and test-retest reli-
ability of blink rate assessment during conversation.
However, comparisons with blink rate in other studies
that use different tests are difficult. Second, the more
stringent criteria for bradykinesia used in the current
study to diagnose DIP [2] is not in line with the UK
brain bank cut-off for PD [18]. However, post-hoc
analysis using the UK brain bank cut-off showed
highly similar results. Third, the UPDRS is the most
Table 2 Sensitivity, specificity and positive and negative predictive value using a 10TH percentile cut off
Percentile N Blink rate per minute Sensitivity Specificity Correctly Classified PPV NPV
10th 101 37-87 100.00% 0.00% 36.98% 22% 63%
9th 94 28-36 92.47% 10.98% 41-.11% 25% 62%
8th 97 23-27 85.71% 21.34% 45.15% 25% 60%
7th 120 18-22 76.88% 30.95% 47.93% 26% 58%
6th 108 15-17 68.05% 44.05% 52.93% 27% 57%
5th 65 13-14 58.70% 55.03% 56.39% 29% 56%
4th 105 10-12 52.21% 61.13% 57.83% 31% 54%
3rd 131 7-9 43.12% 71.80% 61.19% 33% 55%
2nd 88 5-6 27.27% 82.47% 62.06% 34% 56%
1st 132 0-4 16.10% 89.33% 62.25% 35% 83%






0.00 0.25 0.50 0.75 1.00
False Positive Rate (1 - Specificity)
Area under the ROC curve 0.61 95% confidence interval 0.57 - 0.65
Blink rate 10th percentile cut-offs
Fig. 1 Receiver operated curves (ROC) for blink rate as a diagnostic tool for drug-induced parkinsonism using 10th percentile cut offs
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common tool to diagnose PD and is much more
comprehensive than other scales used to measure DIP
[19]. However, a number of experimental instrumental
measurements of both PD [20] and drug-induced
bradykinesia [21] are likely more accurate than the
UPDRS, hence might result in a more accurate diag-
nosis of DIP and possibly a higher sensitivity and spe-
cificity for blink rate. Fourth, repeated measures over
time could result in bias if there were differential
attrition. However, post-hoc analyses with only one
measurement per patient showed very similar results.
Finally, Annamalai et al. [22] found an association
between smoking and nicotine in their impact on the
dopaminergic system. Unfortunately, in the current
study, no data on smoking was available. However, it
is very unlikely that adding a smoking variable to the
logistic regression model would have a substantial
impact on the sensitivity en specificity of the test.
Conclusions
There is a significant association between blink rate and
DIP as diagnosed on the UPDRS. Unfortunately, blink rate
sensitivity and specificity with regard to these outcomes
are too low to replace clinician rating scales in routine
practice. However, there is still a need for an easier and
more accessible way to diagnose movement disorders in
mental health services, as DIP is highly prevalent in SMI
patients [1, 2, 19] and negatively impacts quality of life.
DIP is currently under-diagnosed [19–21], as clinical rat-
ing scales present a number of problems for use in daily
clinical practice [20, 21].Therefore, future research and
clinical practice into diagnosing DIP may be served by
combining blink rate with instrument measurements, e.g.
a finger tapping test, a tremor test and/or a reaction speed
test. All these measures could be programmed as an app
on a mobile device for ease of use. More research needs to






0.00 0.25 0.50 0.75 1.00
False positive rate (1 - Specificity)
Area under ROC curve = 0.7036
Prediction model for DIP using blink rate and clinical variables
Fig. 2 Receiver operated curves (ROC) constructed from the prediction model for drug-induced parkinsonism using blink rate and covariates
Table 3 Prediction model for drug-induced parkinsonism using covariates and continuous blink rate
Odds Ratio p-value 95% Confidence interval
Blink rate per minute 0.97 <0.0000 0.96 0.98
Age 1.04 <0.000 1.03 1.05
Female sex 0.64 0.03 0.44 0.95
Diagnosis other than schizophrenia 1.73 0.01 1.12 2.65
Antipsychotic DDD 1.00 0.96 0.51 0.87
Antipsychotic type
Only FGA 1.83 0.07 0.96 3.50
Only SGA 0.62 0.28 0.26 1.47
Both FGA and SGA 1.58 0.36 0.60 4.20
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